US 8575123
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
granted A61KA61K47/545A61K47/549
Quick answer
US patent 8575123 (Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components) held by Tekmira Pharmaceuticals Corporation expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Tekmira Pharmaceuticals Corporation
- Grant date
- Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 39
- CPC classes
- A61K, A61K47/545, A61K47/549, A61K47/551, A61K47/554